MC2 Therapeutics Announces License and Commercialization Agreement for Wynzora® Cream in Canada

POSTED: November 14, 2024

Copenhagen, November 14, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation, announces today an agreement with Endo, Inc. (OTCQX: ...

READ FULL ARTICLE >

MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy

POSTED: May 13, 2024

• On track to file IND in mid-2025 for a Phase 2b clinical trial in Hidradenitis Suppurativa (“HS”) with MC2-32, a first-in-class, oral drug candidate targeting pathways involved in numerous Immunology and ...

  READ FULL ARTICLE >